Xiangcheng Zhi

Tianjin Medical University Cancer Institute and Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ruifang Niu

Tianjin Medical University Cancer Institute and Hospital

Jin Zhang

Zhejiang University

Xishan Hao

Tianjin Medical University Cancer Institute and Hospital

Jie Ni

Southeast University

Zhen Zhai

Second Affiliated Hospital of Xi'an Jiaotong University

Xiaomeng Hao

Tianjin Medical University Cancer Institute and Hospital

Zhendong Shi

Tianjin Medical University Cancer Institute and Hospital

Yurong Shi

Dalian Maritime University

Jingjing Liu

Baylor College of Medicine

Lei Liu

University Medical Center Groningen

Cooperative Institutions

Tianjin Medical University Cancer Institute and Hospital

Tianjin Medical University

National Clinical Research Center for Digestive Diseases

Tianjin Medical University General Hospital

Zhejiang University

Chinese Academy of Medical Sciences & Peking Union Medical College

Capital Medical University

Ministry of Education of the People's Republic of China

Central South University

Peking University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Human telomerase reverse transcriptase-targeted short hairpin RNA-expressing vector suppresses breast cancer cell proliferation through inhibition of telomerase activity in vitro

Zhonghua shiyan waike zazhi (2013)

Fanguo Hu Xiangcheng Zhi Yu-rong Shi Ruifang Niu Tong Liu

Objective To observe the effects of human telomerase reverse transcriptase (hTERT)directed short hairpin RNA (shRNA)-expressing plasmid on telomerase activity and proliferation in breast cancer cell T47D.Methods hTERT-directed shRNA-expressing plasmid was transfected into T47D cells with liposome.Reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting were used to detect the expression of hTERT mRNA and protein.The telomerase activity was examined by using tartrate resistant acid phosphatase (TRAP)-enzyme linked immunosorbent assay (ELISA).MTT assay was used to draw cell growth line,and cell cycles were detected by using flow cytometry.Results Compared with T47D control group,the expression levels of hTERT mRNA and protein,and telomerase activity in small interfering RNA (siRNA)1 group and siRNA2-N group were decreased with no statistical significance (P＞0.01),while those in siRNA2 group were decreased by 57.1％,57.0％ and 57.0％ (P＜0.01),those in siRNA3 group were decreased by 53.7％,53.4％ and 56.5％ (P ＜0.01),and those in siRNA4 group were decreased by 70.0％,70.3％ and 81.9％ (P ＜0.01),respectively.The cell growth rate and cell cycles in siRNA1 and siRNA2-N groups changed with no statistical significance (P ＞ 0.05),while the cell growth rate in siRNA2,siRNA3 and siRNA4 group was decreased at the first 24 h (P ＜ 0.01),and the cell cycles changed significantly (P ＜ 0.01).Conclusion The hTERT-targeted shRNA-expressing vector can inhibit the proliferation of cancer cells. Key words: Breast carcinoma; Telomerase; RNA interference; Proliferation

MTT assay

10.3760/cma.j.issn.1001-9030.2013.04.006

Cite

Citations (0)

[Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].

Zhonghua yixue zazhi (2011)

Meng-fang Zang Yongmei Zhang Ying-Hui Zhi Zhen Zhai Min Zhang

To compare the chemosensitivity of pirarubicin (THP) and epirubicin (EPI) in primary breast cancer (PBC) cells so as to examine their differential chemosensitivity to THP and EPI by CD-DST (collagen gel droplet embedded culture-drug sensitivity test) system; To detect the differences in the short-term clinical efficacy and side effects between TAC (docetaxel + pirarubicin + cyclophosphamide) and TEC (docetaxel + epirubicin + cyclophosphamide) as the neoadjuvant chemotherapy regimens and the long-term clinical efficacy of CAF (cyclophosphamide + pirarubicin + fluorouracil) and CEF (cyclophosphamide + epirubicin + fluorouracil) as the chemotherapy regimens in breast cancer; To evaluate the feasibility of THP as an adjuvant chemotherapeutic regimen in the treatment of breast cancer.From January 2008 to January 2009, a total of 129 fresh breast cancer samples were collected. The differential chemosensitivity of cultured PBC cells to THP and EPI was measured by CD-DST test. And 139 cases of PBC patients inIIb-IIIc phase were randomly divided into two groups: TAC and TEC groups. After 4-6 cycles of neoadjuvant chemotherapy, the primary lesion, axillary lymph nodes and side effects were assessed; The clinical data and survival status of 1241 cases of PBC patients treated at our hospital from 2003 to 2006 were collected and divided into CAF and CEF groups according to their chemotherapeutic regimens. Long-term prognosis was compared between two groups.There was no significant difference of chemosensitivity between THP and EPI in PBC cells (P = 0.743); The overall response rate (RR) of neoadjuvant chemotherapy was 87.8%; the clinical objective responses, pathologic complete remission (pCR), clinical complete remission (cCR), clinical partial remission (cPR) and stable disease (SD) of groups TAC and TEC were 88.7%, 11.3%, 28.2%, 60.6%, 11.3% vs 86.8%, 10.3%, 26.5%, 60.3%, 13.2% respectively. There was no significant difference between two groups (P > 0.05). No significant differences existed between two groups in such side effects as leukopenia, thrombocytopenia, constipation, cardiotoxity and hepatorenal dysfunction (P > 0.05). The gastrointestinal reactions of nausea and vomiting was less frequent in the TAC group than that in the TEC group (46.5% vs 66.2%, P = 0.019); There was no significant difference in 5-year disease-free survival rate (79% vs 78%) and overall survival rate between two groups (85% vs 82%, P > 0.05).There were no significant differences in chemosensitivity, clinical efficacy of neoadjuvant chemotherapy, side effects or long-term efficacy between THP and EPI. Both pirarubicin and epirubicin may be used as conventional chemotherapy in breast cancer.

Pirarubicin

Epirubicin

Regimen

Source

Cite

Citations (1)

Relationship between expression of cell adhesion molecules and the metastatic mechanism in invasive micropapillary carcinoma of the breast

Chinese Journal of Clinical Oncology (2004)

Fan Yu Li Fu Ronggang Lang Ying Wang Xiangcheng Zhi

10.1007/bf02739854

Cite

Citations (2)

A comparative study on invasive micropapillary carcinoma and invasive ductal carcinoma of the breast

Zhen Zhai Xiaomeng Hao Xiu-fang Tian Jie Ni Xiangcheng Zhi

Objective To elucidate the differences between invasive micropapillary carcinoma (IMPC) and invasive ductal carcinoma(IDC),and explore the clinicopathological and immunohistochemistry characteristics of invasive micropapillary carcinoma of the breast.Methods Invasive micropapillary carcinoma was identified in 51 patients by retrospective review of database from October 2004 to November 2007.Data were compared with 102 patients identified as invasive ductal carcinoma available in this hospital during the same period.Results Significant differences were observed in mammilla invasion,lymphatic vessel invasion,positivity of lymph node,lymph node metastatic level,extranodal extension,estrogen receptor,progestin receptor,triple negative between the two groups; while there was no significant differences between the two groups as to amenorrhea status,lesion laterality,number of metastatic lymph nodes,human epidermal growth factor receptor-2,local recurrence and distant organ metastasis.The median follow-up time of the invasive micropapillary carcinoma group were 46 months ( 16 - 75 months),and the 3-year overall survival and disease free survival was 90.2％ and 84.3％,respectively.Conclusions Invasive micropapillary carcinoma is a unique subtype of breast cancer which manifests an aggressive behavior tending to involve lymph node and extranodal soft tissues.Invasive micropapillary carcinoma of the breast had high expression of hormonal receptors,and triple negative breast cancer is less common in this type of breast cancer. Key words: Breast neoplasms; Carcinoma, ductal, breast; Pathology, clinical; Immunohistochemistry

Lymphovascular invasion

Progesterone receptor

Breast carcinoma

Invasive lobular carcinoma

10.3760/cma.j.issn.1007-631x.2011.12.014

Cite

Citations (0)

Efficacy and feasibility of the immunomagnetic separation based diagnosis for detecting sentinel lymph node metastasis from breast cancer

International Journal of Nanomedicine (2015)

Jin Zhang Xiangcheng Zhi Min Zhang Xiao-Bei Zhang Yan Liu

Abstract: A purpose of this study was to establish a novel molecular diagnostic model and provide new insight into the intraoperative evaluation of the sentinel lymph node (SLN) metastasis in breast cancer. A total of 124 breast cancer patients who met the criteria of sentinel lymph node biopsy (SLNB) and underwent intraoperative biopsy were consecutively enrolled in this study. After the SLNs obtained from each patient were labeled, MOC-31 monoclonal antibody-mediated immunomagnetic separation (IMS) and flow cytometry were used to determine the expressions of breast cancer metastasis-related markers, including Mucin 1 (MUC1), CD44v6, and HER2. Alternatively, conventional intraoperative hematoxylin and eosin (HE) staining and cytokeratin immunohistochemistry (CK-IHC) were performed to detect potential SLN metastasis. The sensitivity, specificity, and false-negative rate of the three intraoperative diagnostic methods were compared and analyzed. A total of 55 positive-SLNs were found in 38 breast cancer patients using IMS, yielding a sensitivity of 86.4% (38/44), specificity of 94.7% (36/38), accuracy of 93.5% (116/124), false-positive rate of 2.5% (2/80), false-negative rate of 13.6% (6/44), positive predictive value of 95.5% (42/44), and negative predictive value of 93.0% (80/86). Patients with high expressions of CD44v6, MUC1, and HER2 in SLNs tended to have higher number of positive lymph nodes, among which the MUC1 and HER2 showed significant differences ( P <0.05). Therefore, compared with conventional HE staining and CK-IHC, IMS technology has remarkably higher sensitivity and specificity and relative lower false-negative rate, thus making it an effective and feasible intraoperative detection method of SLN for breast cancer diagnosis to some extent. Keywords: immunomagnetic separation, breast cancer, sentinel lymph node, MUC1, CD44v6, HER2

Immunomagnetic separation

10.2147/ijn.s72263

Cite

Citations (8)

Clinical analysis of 276 cases of non-palpable TO breast cancer

Chinese Journal of Clinical Oncology (2004)

Yunying Li Shuling Li Xiangcheng Zhi Qian Yu Xilin Fu

Nipple discharge

Axillary lymph nodes

Breast carcinoma

10.1007/bf02739678

Cite

Citations (1)

BRCA1 andBRCA2 sequence variants in Chinese breast cancer families

Human Mutation (2002)

Xiangcheng Zhi Csilla I. Szabo Sandrine Chopin Nicola M. Suter Qing-Sheng Wang

A series of 45 high-risk breast cancer patients, consisting of 25 affected individuals from 16 families in China with at least two cases of breast cancer and 20 cases of breast cancer diagnosed under age 35 without reported family history, were studied for germline mutations of the BRCA1 and BRCA2 genes. Thirteen of the 16 families contained at least one case diagnosed under age 50. Three distinct protein truncating sequence variants, likely to be disease-associated, were identified: two novel mutations in BRCA1 (1584G>T and 5028delC), and a previously reported mutation in BRCA2 (7883delTTAA). Additional sequence variants identified included common polymorphisms, and several variants of unknown clinical significance, including a novel BRCA1 alteration. Based on models for predictive testing using allele frequencies and risks estimated in Western populations, our results suggest that BRCA1/2 mutations account for a somewhat smaller fraction of breast cancer cases in Tianjin than in the Caucasian populations studied. This difference could be the result of a lower penetrance of BRCA1/2 mutations due to the surrounding environmental and hormonal milieu, or a lower frequency of mutations in this population. Larger, more detailed, studies will be necessary to determine which factors underlie this difference.

Penetrance

10.1002/humu.9083

Cite

Citations (45)

Correlation of radiotherapy with prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping

Chinese Journal of Cancer Research (2019)

Xiangcheng Zhi Xiaonan Yang Teng Pan Jingjing Liu Xiaohong Chen

The present study examined the effect of radiotherapy on recurrence and survival in elderly patients with hormone receptor-positive early breast cancer.A retrospective analysis of 327 patients aged ≥65 years, with stage I-II, hormone receptor-positive breast cancer who underwent breast-conserving surgery and received endocrine therapy (ET) or radiotherapy plus endocrine therapy (ET+RT) was performed. Both groups were divided into luminal A type and luminal B type subgroups. Evaluation criteria were 5-year disease-free survival (DFS), local relapse rate (LRR), overall survival (OS), and distant metastasis rate (DMR).There were significant differences in 5-year DFS [hazard ratio (HR)=1.59, 95% confidence interval (95% CI), 1.15-2.19; P=0.005] and LRR (HR=3.33, 95% CI, 1.51-7.34; P=0.003), whereas there were no significant differences in OS and DMR between ET group and ET+RT group. In luminal A type, there was no significant difference in 5-year DFS, LRR, OS and DMR between ET group and ET+RT group. In luminal B type, there were statistically significant differences in 5-year DFS (HR=2.19, 95% CI, 1.37-3.49; P=0.001), LRR (HR=5.45, 95% CI, 1.65-17.98; P=0.005), and OS (HR=1.75, 95% CI, 1.01-3.05; P=0.048) between ET group and ET+RT group. In the ET group, there were significant differences between luminal A type and luminal B type in 5-year DFS (HR=1.84, 95% CI, 1.23-2.75; P=0.003) and OS (HR=1.76, 95% CI, 1.07-2.91; P=0.026).After breast-conserving surgery, radiotherapy can reduce the LRR and improve the DFS and OS of luminal B type elderly patients, whereas luminal A type elderly patients do not benefit from radiotherapy. Without radiotherapy, luminal A type patients have better DFS and OS than luminal B type patients.

Breast-conserving surgery

10.21147/j.issn.1000-9604.2019.03.09

Cite

Citations (7)

BRCA1 Breast Gene Mutations Cancer in Chinese Families with

Yurong Shi U Chenbin Ruifang Niu Xishan Hao Xiangcheng Zhi

Source

Cite

Citations (0)

BRCA1 gene mutations in Chinese families with breast cancer

Chinese Journal of Clinical Oncology (2005)

Yurong Shi LI Chen-bin Ruifang Niu Xishan Hao Xiangcheng Zhi